Maverix Oncology
MaveriX Oncology develops conditionally activated ADCs that co-target cancer cells and the tumor immune microenvironment. Its proprietary TTADC (Targeted-Targeted ADC) platform combines small molecules with ADC payloads to achieve precise activation within tumors, reducing systemic toxicity. MaveriX is focused on solid tumors and metastatic cancers, aiming to improve survival and quality of life. The company’s approach represents a new paradigm in ADC design, offering enhanced selectivity and immune modulation for more effective cancer therapies.
